Protease Inhibitors: all 1,856 studies that test it

Page 3 of 19. Open to participants first (69), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal ImpairmentCompletedNCT03069365Phase 3Results posted
• A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT03067129Phase 2/3Results posted
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerTerminatedNCT03050060Phase 2Results posted
• Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC TaiwanCompletedNCT03020095Phase 2Results posted
• Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China IIICompletedNCT03020082Phase 3Results posted
• Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China IICompletedNCT03020004Phase 2Results posted
• Atazanavir and Endothelial Function in Older HIV PatientsCompletedNCT03019783Phase 2/3Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT03012880Phase 2Results posted
• Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe FibrosisCompletedNCT02973503Phase 3Results posted
• A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 InfectionCompletedNCT02966795Phase 3Results posted
• Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)TerminatedNCT02956629Phase 2Results posted
• A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHDTerminatedNCT02956122Phase 2/3Results posted
• Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic PancreatitisCompletedNCT02947087Phase 1/2Results posted
• The Effect of Ixazomib on the Latent HIV ReservoirCompletedNCT02946047Phase 1/2Results posted
• Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis CCompletedNCT02946034Phase 4Results posted
• Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney TransplantCompletedNCT02945150Phase 4Results posted
• Scale-up of Treatment of Hepatitis C Infection Among People Who Inject DrugsTerminatedNCT02940691Phase 4Results posted
• Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical StudyCompletedNCT02939989Phase 3Results posted
• deLIVER: Direct Acting Antiviral Effects on the LiverCompletedNCT02938013Phase 4Results posted
• Ixazomib Rollover StudyCompletedNCT02924272Phase 2Results posted
• A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02917941Phase 2Results posted
• A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy ParticipantsCompletedNCT02917733Phase 1Results posted
• Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple MyelomaCompletedNCT02916771Phase 2Results posted
• Study of LY3039478 in Healthy ParticipantsCompletedNCT02906618Phase 1Results posted
• HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal TransplantCompletedNCT02902120Phase 4Results posted
• Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell LymphomaTerminatedNCT02898259Phase 1/2Results posted
• Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4CompletedNCT02886624Phase 2Results posted
• PrOD for Non-Cirrhotic Patients With HCV-1b Receiving HemodialysisCompletedNCT02874066Phase 4Results posted
• Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary AngioedemaCompletedNCT02870972Phase 2Results posted
• Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)CompletedNCT02870348Phase 1/2Results posted
• Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin DeficiencyCompletedNCT02870309Phase 1/2Results posted
• A Study of LY3039478 in Japanese Participants With Advanced Solid TumorsCompletedNCT02836600Phase 1Results posted
• Study of Oral Treatments for Hepatitis CCompletedNCT02786537Phase 4Results posted
• Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative RecipientsCompletedNCT02781649Phase 4Results posted
• Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 RearrangementCompletedNCT02765854Phase 2Results posted
• Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)TerminatedNCT02759315Phase 2Results posted
• Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA ExperienceCompletedNCT02745535Phase 2Results posted
• Transplanting Hepatitis C Kidneys Into Negative Kidney RecipientsCompletedNCT02743897Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)CompletedNCT02738138Phase 3Results posted
• Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)TerminatedNCT02736149Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus InfectionCompletedNCT02723084Phase 3Results posted
• Stage 1 Study of ARALAST NP and GLASSIA in A1PI DeficiencyTerminatedNCT02722304Phase 3Results posted
• Anti-inflammatory Therapy to Improve Outcomes After TPIATCompletedNCT02713997Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02707952Phase 3Results posted
• Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)CompletedNCT02700529Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)CompletedNCT02692703Phase 3Results posted
• A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C InfectionCompletedNCT02673489Phase 3Results posted
• A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)CompletedNCT02666352Phase 1Results posted
• A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)CompletedNCT02664558Phase 2Results posted
• A Study of LY3039478 in Healthy ParticipantsCompletedNCT02659865Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 InfectionCompletedNCT02651194Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated CirrhosisCompletedNCT02642432Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 InfectionCompletedNCT02640482Phase 3Results posted
• A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 InfectionCompletedNCT02640157Phase 3Results posted
• Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and CirrhosisCompletedNCT02639338Phase 3Results posted
• The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)CompletedNCT02636595Phase 3Results posted
• Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT02633059Phase 1/2Results posted
• Phase 0 Analysis of Ixazomib (MLN9708) in Patients With GlioblastomaCompletedNCT02630030Early Phase 1Results posted
• THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROCCompletedNCT02625207Phase 1Results posted
• Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT02619682Phase 2Results posted
• Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus InfectionCompletedNCT02609659Phase 3Results posted
• Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral TherapyCompletedNCT02607800Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 InfectionCompletedNCT02604017Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected AdultsCompletedNCT02603107Phase 3Results posted
• Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)CompletedNCT02601573Phase 2Results posted
• Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCVCompletedNCT02600325Phase 3Results posted
• Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 DiabetesCompletedNCT02597101Phase 2Results posted
• A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected AdultsCompletedNCT02582632Phase 3Results posted
• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 2Results posted
• Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral RegimenCompletedNCT02536313Phase 2Results posted
• Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl EstradiolCompletedNCT02533427Phase 1Results posted
• Titrating-Dose of Lonafarnib in Combination With RitonavirCompletedNCT02527707Phase 2Results posted
• GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage StudyCompletedNCT02525861Phase 3Results posted
• A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBLCompletedNCT02518113Phase 1/2Results posted
• ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02517515Phase 3Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of BoneTerminatedNCT02516423Phase 3Results posted
• Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host DiseaseCompletedNCT02513498Phase 2Results posted
• Treatment of Chronic Delta Hepatitis With Lonafarnib and RitonavirCompletedNCT02511431Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular CarcinomaTerminatedNCT02504099Phase 3Results posted
• UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib TreatmentCompletedNCT02499081Phase 2Results posted
• Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected AdultsCompletedNCT02493855Phase 2Results posted
• Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)CompletedNCT02493764Phase 3Results posted
• Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney DiseaseCompletedNCT02487199Phase 3Results posted
• A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric SubjectsCompletedNCT02486406Phase 2/3Results posted
• Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaStatus unknownNCT02481310Phase 1/2Results posted
• Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected AdultsCompletedNCT02476617Phase 3Results posted
• Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal TransplantCompletedNCT02464878Phase 2Results posted
• Study of Clinical Efficacy and Safety of Tosedostat in MDSCompletedNCT02452346Phase 2Results posted
• Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)CompletedNCT02452047Phase 3Results posted
• Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)TerminatedNCT02447887Phase 1/2Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing TherapyCompletedNCT02446717Phase 2/3Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus InfectionCompletedNCT02442284Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in BrazilCompletedNCT02442271Phase 3Results posted
• A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530CompletedNCT02441283Phase 2/3Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)CompletedNCT02440464Phase 2Results posted
• HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02437110Phase 1Results posted
• A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected SubjectsCompletedNCT02431247Phase 3Results posted
• Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)CompletedNCT02430194Phase 2Results posted
• A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02421211Phase 2Results posted
• Ixazomib, Cyclophosphamide and Dexamethasone for Multiple MyelomaCompletedNCT02412228Phase 2Results posted

← Protease Inhibitors overview